Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer medicines based on cell cycle, transcriptional regulation, epigenetics, and mitosis control biology in the United States. Its lead product Plogosertib or plogo, a solid tumors and hematological malignancies, which is in Phase 1/2 clinical trial. The company was founded in 1996 and is headquartered in Kuala… Read more
Cyclacel Pharmaceuticals Inc (CYCC) - Net Assets
Latest net assets as of June 2025: $3.63K USD
Based on the latest financial reports, Cyclacel Pharmaceuticals Inc (CYCC) has net assets worth $3.63K USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($4.40K) and total liabilities ($770.00). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.63K |
| % of Total Assets | 82.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | -106.54% |
| 10-Year Change | -111.54% |
| Growth Volatility | 169.25 |
Cyclacel Pharmaceuticals Inc - Net Assets Trend (2000–2024)
This chart illustrates how Cyclacel Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Cyclacel Pharmaceuticals Inc (2000–2024)
The table below shows the annual net assets of Cyclacel Pharmaceuticals Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.17 Million | -458.15% |
| 2023-12-31 | $607.00K | -97.03% |
| 2022-12-31 | $20.43 Million | -45.79% |
| 2021-12-31 | $37.69 Million | +13.33% |
| 2020-12-31 | $33.26 Million | +184.34% |
| 2019-12-31 | $11.70 Million | -23.41% |
| 2018-12-31 | $15.27 Million | -29.84% |
| 2017-12-31 | $21.77 Million | +52.50% |
| 2016-12-31 | $14.27 Million | -24.22% |
| 2015-12-31 | $18.84 Million | -13.15% |
| 2014-12-31 | $21.69 Million | -22.61% |
| 2013-12-31 | $28.02 Million | +179.70% |
| 2012-12-31 | $10.02 Million | -48.62% |
| 2011-12-31 | $19.50 Million | -21.76% |
| 2010-12-31 | $24.92 Million | +436.69% |
| 2009-12-31 | $4.64 Million | -77.50% |
| 2008-12-31 | $20.64 Million | -64.39% |
| 2007-12-31 | $57.97 Million | +7.51% |
| 2006-12-31 | $53.92 Million | +269.23% |
| 2005-12-31 | $14.60 Million | -66.90% |
| 2004-12-31 | $44.12 Million | +168.04% |
| 2003-12-31 | $-64.84 Million | -34.73% |
| 2002-12-31 | $-48.12 Million | -32.72% |
| 2001-12-31 | $-36.26 Million | -42.85% |
| 2000-12-31 | $-25.38 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Cyclacel Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41032100000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $9.00K | % |
| Other Comprehensive Income | $-891.00K | % |
| Other Components | $438.20 Million | % |
| Total Equity | $-2.17 Million | 100.00% |
Cyclacel Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Cyclacel Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Posti Group Oyj
HE:POSTI
|
$93.24K |
|
Pioneer Acquisition I Corp Units
NASDAQ:PACHU
|
$93.33K |
|
Yulong Eco-Materials Ltd
PINK:YECO
|
$93.35K |
|
Nuveen Dynamic Municipal Opportunities Fund
NYSE:NDMO
|
$93.42K |
|
PPHE Hotel Group Ltd
LSE:PPH
|
$93.20K |
|
Evolution Global Acquisition Corp Units
NASDAQ:EVOXU
|
$93.10K |
|
Baiksan Co. Ltd.
KQ:035150
|
$93.05K |
|
BSGO39
SA:BSGO39
|
$93.05K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Cyclacel Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 607,000 to -2,174,000, a change of -2,781,000 (-458.2%).
- Net loss of 11,212,000 reduced equity.
- New share issuances of 6,209,000 increased equity.
- Other comprehensive income increased equity by 17,000.
- Other factors increased equity by 2,205,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-11.21 Million | -515.73% |
| Share Issuances | $6.21 Million | +285.6% |
| Other Comprehensive Income | $17.00K | +0.78% |
| Other Changes | $2.21 Million | +101.43% |
| Total Change | $- | -458.15% |
Book Value vs Market Value Analysis
This analysis compares Cyclacel Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2000-12-31 | $-2887.83 | $6.37 | x |
| 2001-12-31 | $-4125.14 | $6.37 | x |
| 2002-12-31 | $-5474.97 | $6.37 | x |
| 2003-12-31 | $-7376.56 | $6.37 | x |
| 2004-12-31 | $3805.09 | $6.37 | x |
| 2005-12-31 | $352.05 | $6.37 | x |
| 2006-12-31 | $5607.80 | $6.37 | x |
| 2007-12-31 | $4771.11 | $6.37 | x |
| 2008-12-31 | $1698.93 | $6.37 | x |
| 2009-12-31 | $303.23 | $6.37 | x |
| 2010-12-31 | $1107.00 | $6.37 | x |
| 2011-12-31 | $604.09 | $6.37 | x |
| 2012-12-31 | $334.64 | $6.37 | x |
| 2013-12-31 | $443.75 | $6.37 | x |
| 2014-12-31 | $237.11 | $6.37 | x |
| 2015-12-31 | $138.86 | $6.37 | x |
| 2016-12-31 | $83.35 | $6.37 | x |
| 2017-12-31 | $57.05 | $6.37 | x |
| 2018-12-31 | $25.26 | $6.37 | x |
| 2019-12-31 | $14.33 | $6.37 | x |
| 2020-12-31 | $49.89 | $6.37 | x |
| 2021-12-31 | $63.34 | $6.37 | x |
| 2022-12-31 | $27.23 | $6.37 | x |
| 2023-12-31 | $0.76 | $6.37 | x |
| 2024-12-31 | $-0.26 | $6.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Cyclacel Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -26074.42%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-233.73%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2000 | 0.00% | -13205.10% | 0.00x | 0.00x | $-10.40 Million |
| 2001 | 0.00% | -65040.00% | 0.00x | 0.00x | $-15.89 Million |
| 2002 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.64 Million |
| 2003 | 0.00% | -10857.06% | 0.01x | 0.00x | $-11.97 Million |
| 2004 | -89.73% | -4279.78% | 0.02x | 1.26x | $-44.00 Million |
| 2005 | -438.16% | -5069.66% | 0.02x | 5.21x | $-18.46 Million |
| 2006 | -54.26% | -7560.21% | 0.01x | 1.17x | $-34.65 Million |
| 2007 | -41.49% | -18645.74% | 0.00x | 1.31x | $-29.85 Million |
| 2008 | -195.65% | -4605.02% | 0.03x | 1.50x | $-42.45 Million |
| 2009 | -421.40% | -2148.19% | 0.06x | 3.11x | $-20.03 Million |
| 2010 | -64.28% | -2335.42% | 0.02x | 1.26x | $-18.51 Million |
| 2011 | -78.17% | -2180.69% | 0.03x | 1.33x | $-17.19 Million |
| 2012 | -131.61% | -19110.14% | 0.00x | 1.93x | $-14.19 Million |
| 2013 | -36.23% | -936.62% | 0.03x | 1.27x | $-12.96 Million |
| 2014 | -89.39% | -1118.05% | 0.06x | 1.35x | $-21.56 Million |
| 2015 | -76.15% | -737.76% | 0.08x | 1.31x | $-16.23 Million |
| 2016 | -82.61% | -1398.70% | 0.04x | 1.38x | $-13.22 Million |
| 2017 | -34.32% | 0.00% | 0.00x | 1.19x | $-9.65 Million |
| 2018 | -47.72% | -4858.67% | 0.01x | 1.30x | $-8.82 Million |
| 2019 | -66.92% | 0.00% | 0.00x | 1.31x | $-9.00 Million |
| 2020 | -25.39% | -143695.76% | 0.00x | 1.11x | $-11.77 Million |
| 2021 | -50.11% | 0.00% | 0.00x | 1.14x | $-22.66 Million |
| 2022 | -103.74% | -5683.11% | 0.01x | 1.37x | $-23.24 Million |
| 2023 | -3715.82% | -5370.24% | 0.05x | 14.51x | $-22.62 Million |
| 2024 | 0.00% | -26074.42% | 0.01x | 0.00x | $-10.99 Million |
Industry Comparison
This section compares Cyclacel Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Cyclacel Pharmaceuticals Inc (CYCC) | $3.63K | 0.00% | 0.21x | $93.20K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |